TIDMRENX

RNS Number : 0948E

Renalytix AI PLC

26 February 2020

Renalytix AI plc

("RenalytixAI", the "Company" or the "Group")

Notice of results

Investor briefing

Renalytix AI plc (LSE : RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that it will release its interim results for the six months ended 31 December 2019, on Tuesday 3 March 2020.

Investor briefing

A briefing open to all investors will take place on Monday 9 March 2020 at the Brand Exchange, 3 Birchin Lane, London EC3V 9BW from 5.15pm for a 5.30pm start and will be followed by light refreshments. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email renalytix@walbrookpr.com

For further information, please contact:

 
Renalytix AI plc                                                                    www.renalytixai.com 
James McCullough, CEO                                                                   Via Walbrook PR 
 
Stifel (Nominated Adviser & Joint Broker)                                            Tel: 020 7710 7600 
Alex Price / Jonathan Senior / Ben Maddison 
 
N+1 Singer (Joint Broker)                                                            Tel: 020 7496 3000 
Aubrey Powell / George Tzimas (Corporate Finance) 
Tom Salvesen / Mia Gardner (Corporate Broking) 
 
Walbrook PR Limited                                      Tel: 020 7933 8780 or renalytix@walbrookpr.com 
Paul McManus / Lianne Cawthorne                                          Mob: 07980 541 893 / 07584 391 
                                                                                                    303

About Kidney Disease

Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control estimates there that 15% of United States adults or 37 million people currently have chronic kidney disease. It is reported that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day 13 patients die in the United States while waiting for a kidney transplant.

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

For more information, visit renalytixai.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORSEMFIIESSESE

(END) Dow Jones Newswires

February 26, 2020 02:00 ET (07:00 GMT)

Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Renalytix Charts.
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Renalytix Charts.